Medical News Online | Exclusive Medical Web Content

Web Exclusives

Vedolizumab Tops Adalimumab in Head-to-Head Ulcerative Colitis Trial

Vedolizumab (Entyvio; Takeda), an integrin receptor antagonist, was found to be superior to adalimumab (Humira; AbbVie), a tumor necrosis factor-alpha (TNFα) antagonist, in achieving clinical remission in patients with moderately to severely active ulcerative colitis (UC), according to results from a phase 3b head-to-head trial.

Novel Peptide-Based Immunotherapy Holds Promise for Peanut Allergy

This article is part of Pulmonology Advisor‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019.…

Are E-Cigarettes More Effective Than NRT for Smoking Cessation?

Refillable e-cigarettes demonstrate greater efficacy for smoking cessation than nicotine replacement therapy when both products are accompanied by behavioral support. A 2-group, multicenter, pragmatic, individually randomized controlled trial was conducted at 3 stop-smoking service sites in the United Kingdom as part of the National Health Service (NHS) between May 2015 and February 2018. Results of…
Next post in Web Exclusives